Model Medicines Joins The Fight To Battle The Global COVID-19 Pandemic

Model Medicines has joined the fight to battle the global COVID-19 pandemic. We are harnessing the predictive prowess of our AI Drug Discovery Platform to discover drugs that may be repurposed and serve as therapeutics to prevent individuals from being infected and/or treat individuals infected with the novel coronavirus.

Model Medicines has already identified molecules predicted to bind Angiotensin-Converting Enzyme 2 (ACE2), which may block SARS-CoV-2 spike protein-mediated cell fusion.

We have re-engineered our AI Drug Discovery platform to focus exclusively on ACE2 and other biological targets known to play a role in infection, infection progression and symptoms of infection. Our probabilistic model has shown to be far more effective than existing attempts using deterministic approaches. We have already discovered several leads and are identifying laboratories and partners capable of conducting ACE2 binding assays to experimentally confirm these hits.

The drugs that Model Medicines discovers for COVID-19 can enter clinical trials essentially immediately. Model Medicines drug library is comprised of drugs previously approved by the FDA, and similar, or drugs that have successfully navigated a Phase I clinical trial, at minimum. All drugs have a full pre-clinical program, an existing or legacy supply chain and are known to be safe and well tolerated in humans.